Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cance
Circadian Technologies Limited announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug application from the U.S. Food and Drug Administration to initiate clinical trials of VGX-100.